Skip to content
ClinCalc Pro
Menu
Alkalising Agent / Electrolyte Pregnancy: There are no or limited data from use in pregnant women and animal studies are insufficient with respect to reproductive toxicity. Should not be used during pregnancy unless the clinical condition of the woman requires treatment. Bicarbonate readily crosses the placental barrier, and caution should be exercised in pre-eclampsia due to the high sodium level of the product. Breast-feeding: it is unknown whether sodium bicarbonate/metabolites are excreted in human milk — give only if the benefits clearly outweigh the risks.

Sodium Bicarbonate

Brand names: Minijet Sodium Bicarbonate, Sodium Bicarbonate 8.4%

Used in: Acute Kidney Injury Poisoning & Overdose Hyperkalaemia

Sodium bicarbonate is an alkalinising agent used intravenously to treat severe metabolic acidosis and, in specific settings, to manage hyperkalaemia and certain drug toxicities.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Correction of metabolic acidosis: the dose depends on the degree of the acid-base disorder and is calculated as — mmol sodium bicarbonate = base deficit x kg body weight x 0.2. It is advisable to start by administering only HALF of the calculated dose and to adjust further doses according to the actual results of blood gas analysis.
Route: Intravenous use — for central venous infusion only (Sodium Bicarbonate 8.4% w/v solution for infusion)
Frequency: Further doses adjusted according to blood gas analysis; correction of metabolic acidosis should not be effected too rapidly
Max: Maximum daily dose: according to the correction requirements. Maximum infusion rate: up to 1.5 mmol of sodium bicarbonate per kg body weight per hour.
The factor 0.2 corresponds to the proportion of extracellular fluid in relation to total body weight. SPC worked example: in a patient of 70 kg with a base deficit of 5 mmol/l, 5 x 70 x 0.2 = 70 mmol of sodium bicarbonate (equivalent to 70 ml of Sodium Bicarbonate 8.4% w/v) are to be given — i.e. 1 mmol corresponds to 1 ml of the 8.4% w/v solution. URINE ALKALINISATION: the dose is adjusted according to the desired urine pH, with monitoring of acid-base, water and electrolyte balance, and without exceeding the maximum infusion rate above. In haemodynamically stable adults and children, urine alkalinisation may be achieved with a bolus of 1-2 mmol sodium bicarbonate per kg body weight, followed by an infusion of 132 mmol sodium bicarbonate in 1 litre of glucose 5% in water, with a flow rate of 1.5-2 times the maintenance fluid rate; urine pH should not exceed 8.5. ADMINISTRATION SAFETY: ensure the solution is infused intravenously — accidental intra-arterial infusion may cause shock or loss of an extremity, and accidental paravenous administration may lead to tissue necrosis. If infused undiluted or too rapidly into peripheral veins, 8.4% w/v may cause vein irritation and consequent phlebitis or thrombosis. Monitoring should include regular checks of acid-base balance, serum electrolytes and water balance; alkalinisation promotes potassium influx into cells and may lead to hypokalaemia, so potassium or calcium deficiencies should be corrected before starting alkalinising therapy. Caution is advised in diabetic ketoacidosis, cardiac arrest and lactic acidosis, where effects on organ function, complication rates and survival have not been investigated sufficiently. No renal dose adjustment is stated in the SPC, but caution is required in all situations where sodium intake must be restricted, including severe kidney insufficiency, cardiac insufficiency, oedema, hypertension and eclampsia. NOTE: a US openFDA record was present in this bundle for 'Elliotts B Solution' (an intrathecal diluent for methotrexate sodium and cytarabine) — that is a different product and indication and was NOT used.

Paediatric dose

Dose: 1 mmol/kg
Route: Slow intravenous infusion (central venous infusion only)
Frequency: First dose; thereafter the dosage has to be adjusted individually according to blood gas analysis
Max: In newborns and children under 2 years, the daily dose should not exceed 5 mmol per kg body weight per day
UNIT IS mmol, NOT mg — do not convert or assume milligrams. SPC section 4.2 Paediatric population: 'The dosage has to be adjusted individually. The first dose can be up to 1 mmol/kg body weight, administered by slow intravenous infusion. In newborns and children under 2 years: the daily dose should not exceed 5 mmol per kg body weight per day, administered by slow intravenous infusion.' The 1 mmol/kg figure is an UPPER LIMIT for the first dose ('can be up to'), not a fixed dose. 1 mmol corresponds to 1 ml of the 8.4% w/v solution. In newborns and children under 2 years, 4.2% w/v (or less concentrated) sodium bicarbonate solutions should be preferred, and rapid infusion (10 ml/min) of hypertonic sodium bicarbonate solutions may produce hypernatraemia, a decrease in cerebrospinal fluid pressure and (in preterm infants) possible intracranial haemorrhage. For urine alkalinisation the SPC gives a bolus of 1-2 mmol/kg for haemodynamically stable adults AND children — see adultDose.notes. Verify against a children's formulary before prescribing.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

UNIT IS mmol, NOT mg — do not convert or assume milligrams. SPC section 4.2 Paediatric population: 'The dosage has to be adjusted individually. The first dose can be up to 1 mmol/kg body weight, administered by slow intravenous infusion. In newborns and children under 2 years: the daily dose should not exceed 5 mmol per kg body weight per day, administered by slow intravenous infusion.' The 1 mmol/kg figure is an UPPER LIMIT for the first dose ('can be up to'), not a fixed dose. 1 mmol corresponds to 1 ml of the 8.4% w/v solution. In newborns and children under 2 years, 4.2% w/v (or less concentrated) sodium bicarbonate solutions should be preferred, and rapid infusion (10 ml/min) of hypertonic sodium bicarbonate solutions may produce hypernatraemia, a decrease in cerebrospinal fluid pressure and (in preterm infants) possible intracranial haemorrhage. For urine alkalinisation the SPC gives a bolus of 1-2 mmol/kg for haemodynamically stable adults AND children — see adultDose.notes. Verify against a children's formulary before prescribing.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients
  • Respiratory and metabolic alkalosis
  • Hypoventilation (risk of worsening acidosis)
  • Hypernatraemia
  • Hypokalaemia
  • Excessive chloride loss

Side effects

  • Hypernatraemia (frequency not known)
  • Serum hyperosmolarity (frequency not known)
  • Tissue necrosis following paravenous administration
  • Vein irritation with consequent phlebitis or thrombosis if infused undiluted or too rapidly into peripheral veins (stated in SPC section 4.4)
  • Hypokalaemia — alkalinisation or correction of acidosis promotes potassium influx into cells (stated in SPC section 4.4)

Interactions

  • Urine alkalinisation by sodium bicarbonate accelerates the elimination of acidic drug substances, e.g. acetylsalicylic acid, and delays the elimination of basic drug substances
  • May interact with gluco- and mineralocorticoids, androgens and diuretics, increasing potassium excretion

Clinical monograph

How it works

Bicarbonate ions buffer excess hydrogen ions, raising blood pH, while also promoting an intracellular shift of potassium.

Prescribing in practice

  • Rapid or excessive administration can cause metabolic alkalosis, hypokalaemia, hypernatraemia, fluid overload and a fall in ionised calcium, so it should be reserved for clearly indicated severe acidosis.
  • It is hypertonic and irritant, and extravasation can cause tissue damage; large-vein or central administration is preferred for concentrated solutions.
  • It is incompatible with calcium-containing solutions and many other drugs, which may precipitate in the line.

Monitoring

Monitor arterial blood gases, serum electrolytes including potassium and sodium, and acid-base status during therapy.

Counselling the patient

  • Inform the team that the infusion site should be checked for extravasation.
  • Advise that potassium and pH are rechecked to guide further dosing.

Evidence & guidelines

Its role is supported by acute care and resuscitation guidance, which generally restricts use to severe acidosis and specific indications rather than routine correction.

Reference: Resuscitation Council UK ALS 2021; TOXBASE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.